iTeos Therapeutics, Inc. ITOS
10.15 0.00 (+0.00%)
At closeAug 29, 2025, 4:00 PM EDT
10.15 Day range 10.15
52-week range unavailable
- YTD
- +32.16%
- 1 year
- -40.82%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.00 +146.3% upside
Now 10.15
- Target (low)
- 16.00
- Target (mean)
- 25.00
- Target (high)
- 47.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.02 | -1.48 – -0.78 | -0.85 | -20.2% | 0 | 0.0% | 4 |
| Next quarter | -0.99667 | -1.44 – -0.74 | -1.07 | +6.9% | 0 | 0.0% | 3 |
| Current year | -3.15 | -3.73 – -2.59 | -3.15 | +0.1% | 35.00M | +177.9% | 4 |
| Next year | -3.66 | -5.84 – -2.61 | -3.15 | -16.2% | 7.48M | -78.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 13, 2024 | Wells Fargo | Initiated | — | Overweight |
| Aug 12, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 12, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 13, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 18, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 9, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 17, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 16, 2023 | JP Morgan | Maintained | — | Overweight |
| Mar 16, 2023 | Wedbush | Maintained | — | Outperform |
| May 13, 2022 | SVB Leerink | Maintained | — | Outperform |
| Dec 13, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 12, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 13, 2021 | SVB Leerink | Maintained | — | Outperform |
| May 19, 2021 | SVB Leerink | Maintained | — | Outperform |
| May 5, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Nov 19, 2020 | SVB Leerink | Maintained | — | Outperform |
| Oct 8, 2020 | Baird | Initiated | — | Outperform |
| Aug 18, 2020 | JP Morgan | Initiated | — | Overweight |
| Aug 18, 2020 | Wedbush | Initiated | — | Outperform |
| Aug 18, 2020 | SVB Leerink | Initiated | — | Outperform |
| Aug 18, 2020 | Piper Sandler | Initiated | — | Overweight |